<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433560</url>
  </required_header>
  <id_info>
    <org_study_id>KKKR-Neulasta OS-01</org_study_id>
    <nct_id>NCT03433560</nct_id>
  </id_info>
  <brief_title>An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)</brief_title>
  <official_title>An Observational, Prospective, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Korea Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate real-world safety and efficacy of&#xD;
      pegfilgrastim (Neulasta) administered as secondary prophylaxis in Korean female patients with&#xD;
      breast cancer receiving chemotherapy regimens recently covered under national health&#xD;
      insurance. This is a prospective, observational, open-label trial with a target enrollment of&#xD;
      1400 subjects.&#xD;
&#xD;
      Primary endpoint The primary aim of this study is to determine the incidence of febrile&#xD;
      neutropenia.&#xD;
&#xD;
      Secondary endpoint Major secondary endpoint include a) Incidence of bone pain, b) All adverse&#xD;
      events, c) Percentage of patients with RDI (relative dose intensity) ≥ 85%&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of febrile neutropenia after secondary prophylaxis with pegfilgrastim</measure>
    <time_frame>From the cycle of chemotherapy before administration of next cycle of chemotherapy (approximately 3weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of bone pain, or percentage of patients with relative dose intensity (RDI) or all adverse events as assessed by CTCAE</measure>
    <time_frame>During the study period (~ 1months follow-up)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1300</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Breast Neoplasm Female</condition>
  <arm_group>
    <arm_group_label>Korean female breast cancer patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Please refer to the inclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 19 years old, and ≤ 64 years old, and&#xD;
&#xD;
          -  Female patients with breast cancer receiving chemotherapy recently covered under&#xD;
             national health insurance (only chemotherapy regimens in the table below), and&#xD;
&#xD;
          -  Patients with neutropenic events (febrile neutropenia or grade 4 neutropenia) in any&#xD;
             previous cycle that did not use G-CSF for the prevention of neutropenia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any of the followings are excluded.&#xD;
&#xD;
          -  Patients with a history of allergic reactions to E-coli derived proteins, human&#xD;
             granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim&#xD;
&#xD;
          -  Uses for off-label indications such as chronic myelogenous leukemia, myelodysplastic&#xD;
             syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucheon Soonchunhyang University Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Kyounggi</state>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Kyoungsang</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>febrile neutropenia</keyword>
  <keyword>neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

